{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:47:42Z","timestamp":1792320462884,"version":"4.4.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Linezolid is an oxazolidinone antibiotic that is active against drug-resistant Gram-positive bacteria and multidrug-resistant\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    . Real-world studies on the safety of linezolid in large populations are lacking. This study aimed to determine the adverse events associated with linezolid in real-world settings by analyzing data from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We retrospectively extracted reports on adverse drug events (ADEs) from the FAERS database from the first quarter of 2004 to that of 2023. By using disproportionality analysis including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), along with the multi-item gamma Poisson shrinker (MGPS), we evaluated whether there was a significant association between linezolid and ADE. The time to onset of ADE was further analyzed in the general population and within each age, weight, reporting population, and weight subgroups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    A total of 11,176 reports of linezolid as the \u201cprimary suspected\u201d drug and 263 significant adverse events of linezolid were identified, including some common adverse events such as thrombocytopenia (\n                    <jats:italic>n<\/jats:italic>\n                    = 1,139, ROR 21.98), anaemia (\n                    <jats:italic>n<\/jats:italic>\n                    = 704, ROR 7.39), and unexpected signals that were not listed on the drug label such as rhabdomyolysis (\n                    <jats:italic>n<\/jats:italic>\n                    = 90, ROR 4.33), and electrocardiogram QT prolonged (\n                    <jats:italic>n<\/jats:italic>\n                    = 73, ROR 4.07). Linezolid-induced adverse reactions involved 27 System Organ Class (SOC). Gender differences existed in ADE signals related to linezolid. The median onset time of all ADEs was 6 days, and most ADEs (\n                    <jats:italic>n<\/jats:italic>\n                    = 3,778) occurred within the first month of linezolid use but some may continue to occur even after a year of treatment (\n                    <jats:italic>n<\/jats:italic>\n                    = 46).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    This study reports the time to onset of adverse effects in detail at the levels of SOC and specific preferred term (PT). The results of our study provide valuable insights for optimizing the use of linezolid and reducing potential side effects, expected to facilitate the safe use of linezolid in clinical settings.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2024.1338902","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T23:59:33Z","timestamp":1708041573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":112,"title":["Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Fan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjie","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and drug administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2146\/ajhp080228","article-title":"Elevated creatine phosphokinase levels associated with linezolid therapy","volume":"66","author":"Allison","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e2247426","DOI":"10.1001\/jamanetworkopen.2022.47426","article-title":"Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants","volume":"5","author":"Bai","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-022-01125-2","article-title":"A review of population pharmacokinetic analyses of linezolid","volume":"61","author":"Band\u00edn-Vilar","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"877932","DOI":"10.3389\/fphar.2022.877932","article-title":"Antibiotic-induced neutropenia in pediatric patients: new insights from pharmacoepidemiological analyses and a systematic review","volume":"13","author":"Battini","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e01741","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"mBio"},{"key":"B8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/cid\/cis293","article-title":"Rhabdomyolysis in a patient treated with linezolid for extensively drug-resistant tuberculosis","volume":"54","author":"Carroll","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10096-019-03754-1","article-title":"Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients","volume":"39","author":"Cazavet","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cgh.2017.11.025","article-title":"Advantages and limitations of the federal adverse events reporting system in assessing adverse event reporting for eluxadoline","volume":"16","author":"Chedid","year":"2018","journal-title":"Clin. Gastroenterology Hepatology Official Clin. Pract. J. Am. Gastroenterological Assoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03256733","article-title":"Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods","volume":"22","author":"Chen","year":"2008","journal-title":"Pharm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jval.2015.04.007","article-title":"Linezolid versus vancomycin in the empiric treatment of nosocomial pneumonia: a cost-utility analysis incorporating results from the ZEPHyR trial","volume":"18","author":"Collins","year":"2015","journal-title":"Value Health"},{"key":"B16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s11739-022-02999-7","article-title":"Sex and gender differences in community-acquired pneumonia","volume":"17","author":"Corica","year":"2022","journal-title":"Intern Emerg. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","article-title":"A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data","volume":"35","author":"Cornelius","year":"2012","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5588\/ijtld.11.0451","article-title":"Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"16","author":"Cox","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e00605-19","DOI":"10.1128\/aac.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/jcpt.13245","article-title":"Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA adverse event reporting system","volume":"45","author":"Dai","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","article-title":"Sex differences in adverse drug reactions of metformin: a longitudinal survey study","volume":"43","author":"de Vries","year":"2020","journal-title":"Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fort\u00fan","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"Francescangeli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1002789","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/14740338.2021.1956461","article-title":"Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system","volume":"20","author":"Gatti","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00228-020-02990-1","article-title":"Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic\/pharmacodynamic analysis","volume":"77","author":"Gatti","year":"","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/dddt.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1183\/13993003.01374-2015","article-title":"Linezolid in drug-resistant tuberculosis: haste makes waste","volume":"46","author":"Hughes","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1021\/jm800379d","article-title":"Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit","volume":"51","author":"Ippolito","year":"2008","journal-title":"J. Med. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1111\/bcp.15460","article-title":"Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA adverse event reporting system","volume":"88","author":"Ji","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1111\/bcp.15460","article-title":"Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: data mining of the FDA adverse event reporting system","volume":"88","author":"Ji","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1086\/597298","article-title":"A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic leukemia","volume":"48","author":"Joshi","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/MJT.0b013e3181a59bcd","article-title":"Black tongue associated with linezolid","volume":"17","author":"Jover-Diaz","year":"2010","journal-title":"Am. J. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"004041","DOI":"10.12890\/2023_004041","article-title":"Linezolid-induced pancreatitis associated with lactic acidosis and relative hypoglycemia: a rare case report","volume":"10","author":"Kim","year":"","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"","journal-title":"Nucleic Acids Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/jac\/dks078","article-title":"Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients","volume":"67","author":"Koh","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"101790","DOI":"10.1016\/j.eclinm.2022.101790","article-title":"Oral minocycline plus rifampicin versus oral linezolid for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: the AIDA open label, randomized, controlled Phase 4 trial","volume":"56","author":"Kotsaki","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"106843","DOI":"10.1016\/j.ijantimicag.2023.106843","article-title":"Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents","volume":"62","author":"Kufel","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B49","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s15010-016-0978-8","article-title":"Two cases of serious rhabdomyolysis during linezolid treatment","volume":"45","author":"Lechner","year":"2017","journal-title":"Infection"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1086\/379012","article-title":"Linezolid-associated toxic optic neuropathy: a report of 2 cases","volume":"37","author":"Lee","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e01453-17","DOI":"10.1128\/aac.01453-17","article-title":"Thrombocytopenia with tedizolid and linezolid","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"368504211042982","DOI":"10.1177\/00368504211042982","article-title":"Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: a case report","volume":"104","author":"Lee","year":"2021","journal-title":"Sci. Prog."},{"key":"B53","doi-asserted-by":"publisher","first-page":"116385","DOI":"10.1016\/j.socscimed.2023.116385","article-title":"A Gender Hypothesis of sex disparities in adverse drug events","volume":"339","author":"Lee","year":"2023","journal-title":"Soc. Sci. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","article-title":"Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases","volume":"14","author":"Leroy","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20171125","article-title":"Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis","volume":"38","author":"Li","year":"2018","journal-title":"Biosci. Rep."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","author":"Li","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1253799","DOI":"10.3389\/fphar.2023.1253799","article-title":"Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Lifan","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.1128\/aac.00644-10","article-title":"Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance","volume":"54","author":"Long","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/aac.05702-11","article-title":"Resistance to linezolid caused by modifications at its binding site on the ribosome","volume":"56","author":"Long","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jac\/dkf215","article-title":"The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin","volume":"50","author":"Moise","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"E29","DOI":"10.1086\/340982","article-title":"Linezolid-induced pure red blood cell aplasia","volume":"35","author":"Monson","year":"2002","journal-title":"Clin. Infect. Dis. Official Publ. Infect. Dis. Soc. Am."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s15010-014-0674-5","article-title":"Risk factors for linezolid-associated thrombocytopenia in adult patients","volume":"42","author":"Natsumoto","year":"2014","journal-title":"Infection"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"872854","DOI":"10.3389\/fphar.2022.872854","article-title":"Stevens-johnson syndrome following vancomycin and linezolid: a real-world analysis of post-marketing surveillance data","volume":"13","author":"Ni","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.clinthera.2014.06.029","article-title":"Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid","volume":"36","author":"Niederman","year":"2014","journal-title":"Clin. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1128\/aac.00948-12","article-title":"A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections","volume":"56","author":"Noel","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/dddt.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/s1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O'Riordan","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijantimicag.2010.10.001","article-title":"Linezolid-related immune-mediated severe thrombocytopenia","volume":"37","author":"Pascoalinho","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B76","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","article-title":"Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial","volume":"309","author":"Prokocimer","year":"2013","journal-title":"Jama"},{"key":"B77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5772\/intechopen.79986","article-title":"Evolving roles of spontaneous reporting systems to assess and monitor drug safety","volume-title":"Pharmacovigilance","author":"Raschi","year":"2019"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.5588\/ijtld.12.0322","article-title":"Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children","volume":"16","author":"Rose","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis. Official J. Int. Union Against Tuberc. Lung Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"B81","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1053\/j.ajkd.2009.07.013","article-title":"Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"54","author":"Savard","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.2147\/idr.S373266","article-title":"Oral bacteria dysbiosis in patients with linezolid-induced black hairy tongue: a case series","volume":"15","author":"Shangguan","year":"2022","journal-title":"Infect. Drug Resist"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/bcp.15587","article-title":"Linezolid and the risk of QT interval prolongation: a pharmacovigilance study of the food and drug administration adverse event reporting system","volume":"89","author":"Shao","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.1038\/s41598-021-86869-w","article-title":"Assortative social mixing and sex disparities in tuberculosis burden","volume":"11","author":"Shaweno","year":"2021","journal-title":"Sci. Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00198-023-06877-6","article-title":"A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS)","volume":"34","author":"Shi","year":"","journal-title":"Osteoporos. Int. a J. Established as Result Coop. Between Eur. Found. Osteoporos. Natl. Osteoporos. Found. U. S. A."},{"key":"B88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12519-022-00650-1","article-title":"Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis","volume":"19","author":"Shi","year":"","journal-title":"World J. Pediatr."},{"key":"B89","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1128\/aac.03688-14","article-title":"Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections","volume":"59","author":"Shorr","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"Singh","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00228-001-0380-y","article-title":"Age and sex effects on the pharmacokinetics of linezolid","volume":"57","author":"Sisson","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur. Respir. J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","article-title":"A systematic review on the definition of rhabdomyolysis","volume":"267","author":"Stahl","year":"2020","journal-title":"J. Neurol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1017\/s0950268822000735","article-title":"Circulating sex-steroids and Staphylococcus aureus nasal carriage in a general male population","volume":"150","author":"Stensen","year":"2022","journal-title":"Epidemiol. Infect."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1248\/bpb.b16-00427","article-title":"Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2","volume":"39","author":"Tajima","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"B98","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e15417","DOI":"10.1111\/ped.15417","article-title":"Linezolid-induced black hairy tongue in a child following osteomyelitis","volume":"65","author":"Tomita","year":"2023","journal-title":"Pediatr. Int."},{"key":"B100","doi-asserted-by":"publisher","first-page":"ofac331","DOI":"10.1093\/ofid\/ofac331","article-title":"A cross-sectional analysis of linezolid in combination with methadone or buprenorphine as a cause of serotonin toxicity","volume":"9","author":"Traver","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","article-title":"Identification of substandard medicines via disproportionality analysis of individual case safety reports","volume":"40","author":"Trippe","year":"2017","journal-title":"Drug Saf."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00228-021-03221-x","article-title":"Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study","volume":"78","author":"Tsutsumi","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1093\/jac\/dkad276","article-title":"Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects","volume":"78","author":"Veerman","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cmi.2017.02.011","article-title":"Comparing the cost-effectiveness of linezolid to trimethoprim\/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective","volume":"23","author":"von Dach","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B107","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/j.1399-3062.2012.00728.x","article-title":"Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation","volume":"14","author":"Waki","year":"2012","journal-title":"Transpl. Infect. Dis. Official J. Transplant. Soc."},{"key":"B108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2041-1480-5-36","article-title":"Standardizing adverse drug event reporting data","volume":"5","author":"Wang","year":"2014","journal-title":"J. Biomed. Semant."},{"key":"B109","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40261-015-0352-0","article-title":"Thrombocytopenia in patients receiving prolonged linezolid may be caused by oxidative stress","volume":"36","author":"Wang","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","author":"Wang","year":"2023","journal-title":"Andrology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/bdd.255","article-title":"Linezolid absolute bioavailability and the effect of food on oral bioavailability","volume":"22","author":"Welshman","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"B112","doi-asserted-by":"publisher","first-page":"13339","DOI":"10.1073\/pnas.0804276105","article-title":"The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning","volume":"105","author":"Wilson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B113","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1345\/aph.1R386","article-title":"Clinical relevance of linezolid-associated serotonin toxicity","volume":"47","author":"Woytowish","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"B114","doi-asserted-by":"publisher","first-page":"844567","DOI":"10.3389\/fphar.2022.844567","article-title":"Dosage strategy of linezolid according to the trough concentration target and renal function in Chinese critically ill patients","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B116","doi-asserted-by":"publisher","first-page":"e710","DOI":"10.1093\/cid\/ciab032","article-title":"A phase 3, randomized, double-blind study comparing tedizolid phosphate and linezolid for treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia","volume":"73","author":"Wunderink","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B117","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.2147\/IDR.S362358","article-title":"Linezolid-induced pure red cell aplasia: a case report","volume":"15","author":"Yang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B118","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","article-title":"A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1338902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T23:59:39Z","timestamp":1708041579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1338902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":115,"alternative-id":["10.3389\/fphar.2024.1338902"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1338902","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"article-number":"1338902"}}